Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

NAActive, not recruitingINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Multiple Myeloma, Neoplasms

Interventions

DRUG

Aponermin, pomalidomide, dexamethasone

Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days.

Trial Locations (2)

Peking University People's Hospital, Beijing

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT06924424 - Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter